未登录A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosusvan Vollenhoven RF, Wang L, Merrill JT, Liu Y, Bao C, Li F, 等. 针对系统性红斑狼疮的teletacicept III期临床试验。N Engl J Med. (2025) 393:1475–85. doi: 10.1056/NEJMoa2414719
van Vollenhoven, Ronald F.; Wang, Li; Merrill, Joan T.; Liu, Yi; Bao, Chunde; Li, Fen; Hu, Jiankang; Huang, Chenghui; Zhao, Jianhong; Huang, Cibo; Mo, Hanyou; Wei, Wei; Lu, Fu'ai; Li, Jingyang; Zhao, Dongbao; Wang, Wenxiang; Li, Lin; Zuraw, Qing; Wang, Xiaofei; Wang, Xuebin; Fang, Jianmin; Zhang, Fengchun .png)
分享.png)
收藏Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial CancerDisitamab vedotin联合toripalimab在HER2表达型晚期尿路上皮癌中的应用Sheng, Xinan; Zeng, Gongqian; Zhang, Cuijian; Zhang, Qingyun; Bian, Jiasheng; Niu, Haitao; Li, Jun; Shi, Yanxia; Yao, Kai; Hu, Bin; Liu, Ziling; Liao, Hong; Yu, Zhixian; Jin, Baiye; Zhao, Peng; Yang, Tiejun; Liu, Xianling; Qin, Yang; Xue, Xueyi; Gou, Xin; Huang, Jian; Gu, Jiang; Qi, Xiaolong; Zhang, Lu; Ma, Guoxian; Liu, Beisong; Fang, Jianmin; Jiang, Shusuan; He, Zhisong; Zhou, Aiping; Guo, Jun 分享 收藏 分享 收藏 分享 收藏 分享 收藏 分享 收藏 Mesencephalic astrocyte-derived neurotrophic factor alleviated 6-OHDA-induced cell damage via ROS-AMPK/mTOR mediated autophagic inhibition (vol 89, pg 45, 2017)Zhang, Jingxing; Cai, Qiong; Jiang, Ming; Liu, Yigang; Gu, Hua; Guo, Jia; Sun, Hui; Fang, Jianmin; Jin, Lingjing 分享 收藏 分享 收藏 Simultaneous inhibition of fibroblast growth factor-2 and vascular endothelial growth factor-a with RC28-E in diabetic macular edema: a phase 2 randomised trialZhang, Wenfei; Cheng, Shiyu; Gu, Xingwang; Liu, Xinyu; Dai, Hong; Zhuang, Wenjuan; Sun, Bin; Gao, Lei; Sun, Xuguang; Zhang, Ming; Song, Zongming; Wang, Wenxiang; Li, Lin; Chen, He; Fang, Jianmin; Chen, Youxin 分享 收藏 A phase II safety and efficacy study of PM8002/BNT327 in combination with chemotherapy in patients with EGFR-mutated non-small cell lung cancer (NSCLC)一项关于PM8002/BNT327联合化疗在EGFR突变非小细胞肺癌（NSCLC）患者中的安全性和有效性II期研究Wu, Y-L.; Wang, Z.; Cheng, Y.; Fang, J.; Meng, X.; Pan, Y.; Zhao, H.; Zhao, Y.; Su, H.; Sun, M.; Zhou, T.; Duan, P.; Lv, D.; Wang, Y.; Du, Y.; Zuo, W.; Zhang, P.; Zhang, T. 分享 收藏 Therapeutic Targeting Tongue Squamous Cell Carcinoma via ICAM1 Antibody-Drug Conjugates in Preclinical Models在临床前模型中通过ICAM1抗体-药物缀合物靶向治疗舌鳞状细胞癌Ma, Letao; Xu, Yanzhi; Yang, Yuxuan; Yang, Teng; Dai, Yujie; Shimura, Takaya; Sha, Chulin; Li, Xinfang; Fang, Jianmin; Zheng, Weihui; Lu, Ye; Guo, Peng 分享 收藏 Disitamab vedotin, a HER2-directed antibody-drug conjugate, in patients with HER2-overexpression and HER2-low advanced breast cancer: a phase I/Ib studyHER2-overexpression和HER2-low晚期乳腺癌患者的HER2-directed抗体药物偶联物Disitamab vedotin: I/Ib期研究Wang, Jiayu; Liu, Yunjiang; Zhang, Qingyuan; Li, Wei; Feng, Jifeng; Wang, Xiaojia; Fang, Jianmin; Han, Yiqun; Xu, Binghe 分享 收藏 Effect of Telitacicept on Circulating Gd-IgA1 and IgA-Containing Immune Complexes in IgA NephropathyZan, Jincan; Liu, Lijun; Li, Guisen; Zheng, Hongguang; Chen, Nan; Wang, Caili; Xie, Deqiong; Zuo, Li; Li, Rongshan; Zhang, Pengfei; Wang, Yue; Wang, Wenxiang; Li, Lin; Fang, Jianmin; Lv, Jicheng; Zhang, Hong 分享 收藏 分享 收藏 Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trialWang, Yakun; Gong, Jifang; Wang, Airong; Wei, Jia; Peng, Zhi; Wang, Xicheng; Zhou, Jun; Qi, Changsong; Liu, Dan; Li, Jian; Lu, Ming; Lu, Zhihao; Cao, Yanshuo; Yuan, Jiajia; Zhang, Ruyan; Fang, Jianmin; Zhang, Xiaotian; Shen, Lin 分享 收藏 Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancerLei, Huizi; Ling, Yun; Yuan, Pei; Yan, Xieqiao; Wang, Lin; Shi, Yanxia; Yao, Xin; Luo, Hong; Shi, Benkang; Liu, Jiyan; He, Zhisong; Yu, Guohua; Han, Weiqing; Hu, Changlu; Chi, Zhihong; Cui, Chuanliang; Si, Lu; Fang, Jianmin; Guo, Jun; Sheng, Xinan; Zhou, Aiping; Ying, Jianming 分享 收藏 分享 收藏 Randomized Phase 2 Trial of Telitacicept in Patients With IgA Nephropathy With Persistent Proteinuria特利他西普治疗伴持续性蛋白尿的IgA肾病患者的随机化II期临床试验Lv, Jicheng; Liu, Lijun; Hao, Chuanming; Li, Guisen; Fu, Ping; Xing, Guangqun; Zheng, Hongguang; Chen, Nan; Wang, Caili; Luo, Ping; Xie, Deqiong; Zuo, Li; Li, Rongshan; Mao, Yonghui; Dong, Shaoshao; Zhang, Pengfei; Zheng, Huixiao; Wang, Yue; Qin, Wei; Wang, Wenxiang; Li, Lin; Jiao, Wenjuan; Fang, Jianmin; Zhang, Hong 分享 收藏 Targeting CD89 on tumor-associated macrophages overcomes resistance to immune checkpoint blockade靶向肿瘤相关巨噬细胞上的CD89克服了对免疫检查点阻断的抗性Xu, Lijun; Li, Bingyu; Pi, Chenyu; Zhu, Zhaohua; Tao, Fei; Xie, Kun; Feng, Yan; Xu, Xiaoqing; Yin, Yanxin; Gu, Hua; Fang, Jianmin 分享 收藏 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png)
